Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).

Brian Dougherty(AstraZeneca (United States)), J. Carl Barrett(National Institute of Environmental Health Sciences), Timothy J. Brennan(University of Iowa Hospitals and Clinics), Tony W. Ho(Johns Hopkins University), Mark J. O’Connor(AstraZeneca (United Kingdom)), Anitra Fielding(AstraZeneca (United States)), Matthew Hawryluk(Foundation Medicine (United States)), Jonathan A. Ledermann(London Cancer), Roman Yelensky(National Vaccine and Serum Institute), Darren Hodgson(AstraZeneca (United Kingdom)), Zhongwu Lai(AstraZeneca (United States)), Jane Robertson(Cancer Research UK), James Sun(GlobalFoundries (United States))
Journal of Clinical Oncology
May 20, 2014
10.1200/jco.2014.32.15_suppl.5536
Cited by 3

Related Papers

The complete genome sequence of the gastric pathogen Helicobacter pylori
|Nature|1997|3.6k
Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council
|Journal of Pain|2016|3.2k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
The Genome Sequence of the Malaria Mosquito <i>Anopheles gambiae</i>
|Science|2002|2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k